These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 28425821)

  • 21. Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy.
    Villalba Martínez G; Fernández-Candil JL; Vivanco-Hidalgo RM; Pacreu Terradas S; León Jorba A; Arroyo Pérez R
    Rev Esp Anestesiol Reanim; 2015 May; 62(5):275-9. PubMed ID: 25475698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Familial hyperinsulinism-hyperammonemia syndrome in a family with seizures: case report.
    de las Heras J; Garin I; de Nanclares GP; Aguayo A; Rica I; Castaño L; Vela A
    J Pediatr Endocrinol Metab; 2010 Aug; 23(8):827-30. PubMed ID: 21073125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Burst Suppression Pattern on Electroencephalogram Secondary to Valproic Acid-Induced Hyperammonemic Encephalopathy.
    Cherian KA; Legatt AD
    Pediatr Neurol; 2017 Aug; 73():88-91. PubMed ID: 28545673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous use of valproic acid in status epilepticus is associated with high risk of hyperammonemia.
    Lind J; Nordlund P
    Seizure; 2019 Jul; 69():20-24. PubMed ID: 30953957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effect of Carnitine Supplementation on Hyperammonemia and Carnitine Deficiency Treated with Valproic Acid in a Psychiatric Setting.
    Nakamura M; Nagamine T
    Innov Clin Neurosci; 2015; 12(9-10):18-24. PubMed ID: 26634177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperammonemia and coma developed by a woman treated with valproic acid for affective disorder.
    Eze E; Workman M; Donley B
    Psychiatr Serv; 1998 Oct; 49(10):1358-9. PubMed ID: 9779913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [L-carnitine in valproic acid-induced hyperammonemia].
    Martín-del Rincón JP; Llompart-Pou JA; Ferreruela M; Velasco J
    Med Intensiva; 2014 Mar; 38(2):124-5. PubMed ID: 23017629
    [No Abstract]   [Full Text] [Related]  

  • 29. L-carnitine for acute valproic acid overdose: a systematic review of published cases.
    Perrott J; Murphy NG; Zed PJ
    Ann Pharmacother; 2010; 44(7-8):1287-93. PubMed ID: 20587742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carnitine deficiency during valproic acid treatment.
    Van Wouwe JP
    Int J Vitam Nutr Res; 1995; 65(3):211-4. PubMed ID: 8830002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease).
    Larsen EP; Ostergaard JR
    Seizure; 2014 Jun; 23(6):429-34. PubMed ID: 24647346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levocarnitine induced seizures in patients on valproic acid: A negative systematic review.
    Zeiler FA; Sader N; Gillman LM; West M
    Seizure; 2016 Mar; 36():36-39. PubMed ID: 26889779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?
    Lheureux PE; Penaloza A; Zahir S; Gris M
    Crit Care; 2005 Oct; 9(5):431-40. PubMed ID: 16277730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valproic acid-induced encephalopathy: A review of clinical features, risk factors, diagnosis, and treatment.
    Wu J; Li J; Jing W; Tian X; Wang X
    Epilepsy Behav; 2021 Jul; 120():107967. PubMed ID: 34004407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hyperammonemia secondary to the use of valproic acid: case report].
    Turcato Mde F; Fernandes RM; Wichert-Ana L; Funayama CA
    Arq Neuropsiquiatr; 2005 Jun; 63(2A):364-6. PubMed ID: 16100994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carnitine as an antidote for acute valproate toxicity in children.
    Russell S
    Curr Opin Pediatr; 2007 Apr; 19(2):206-10. PubMed ID: 17496767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. L-carnitine supplementation in childhood epilepsy: current perspectives.
    De Vivo DC; Bohan TP; Coulter DL; Dreifuss FE; Greenwood RS; Nordli DR; Shields WD; Stafstrom CE; Tein I
    Epilepsia; 1998 Nov; 39(11):1216-25. PubMed ID: 9821988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum biotinidase activity in children treated with valproic acid and carbamazepine.
    Castro-Gago M; Gómez-Lado C; Eirís-Puñal J; Díaz-Mayo I; Castiñeiras-Ramos DE
    J Child Neurol; 2010 Jan; 25(1):32-5. PubMed ID: 19458381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valproic acid and secondary hyperammonemia.
    Rawat S; Borkowski WJ; Swick HM
    Neurology; 1981 Sep; 31(9):1173-4. PubMed ID: 6791053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of L-carnitine supplementation on acute valproate intoxication.
    Murakami K; Sugimoto T; Woo M; Nishida N; Muro H
    Epilepsia; 1996 Jul; 37(7):687-9. PubMed ID: 8681902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.